机译:Afatinib在肺腺癌患者中产生的疗效,涉及HER2 S310Y突变
Jinan Univ Clin Med Coll 2 Shenzhen Peoples Hosp Dept Thorac Surg 1017 North Dongmen Rd;
Jinan Univ Clin Med Coll 2 Shenzhen Peoples Hosp Dept Thorac Surg 1017 North Dongmen Rd;
Jinan Univ Clin Med Coll 2 Shenzhen Peoples Hosp Dept Thorac Surg 1017 North Dongmen Rd;
Jinan Univ Clin Med Coll 2 Shenzhen Peoples Hosp Dept Thorac Surg 1017 North Dongmen Rd;
Burning Rock Biotech 7 Luoxuan 4th Rd Guangzhou Guangdong Peoples R China;
Burning Rock Biotech 7 Luoxuan 4th Rd Guangzhou Guangdong Peoples R China;
Burning Rock Biotech 7 Luoxuan 4th Rd Guangzhou Guangdong Peoples R China;
Jinan Univ Clin Med Coll 2 Shenzhen Peoples Hosp Dept Thorac Surg 1017 North Dongmen Rd;
adenocarcinoma; HER2 S310Y; afatinib; next-generation sequencing; targeted therapy;
机译:Afatinib在肺腺癌患者中产生的疗效,涉及HER2 S310Y突变
机译:阿法替尼作为携带HER2突变的晚期肺腺癌患者的一线治疗:一例病例报告并文献复习
机译:阿法替尼对具有罕见EGFR delE709_T710insD突变的肺腺癌患者的巨大疗效:一例报告
机译:肺腺癌的EGFR突变:与F-18 FDG PET / CT的相关性
机译:与表皮生长因子受体基因激活突变有关的肺腺癌疾病病程特征。
机译:阿法替尼产生的具有HER2 S310Y突变的肺腺癌患者的疗效
机译:Afatinib在肺腺癌患者中产生的疗效,涉及HER2 S310Y突变